Osteoporosis
The Disease
Osteoporosis is a metabolic disease characterized by decreased bone mass and density that unavoidably lead to bone fragility and increased incidence of fractures.
Evaluation Platform
The TghRANKL mouse model spontaneously develops osteoporosis pathology from the first weeks of age with 100% penetrance due to the overexpression of human RANKL. Mice can be treated either prophylactically -at disease onset- or therapeutically –at established pathology- with protocols standardized for the evaluation of a variety of therapeutics. Disease progress and severity are assessed regularly using validated readouts with standardized procedures.
Mice can be treated with protocols standardized for the evaluation of a variety of therapeutics. Disease severity is assessed using validated readouts with standardized procedures.
Read-Out Parameters
TRAcP serum levels
Histopathological evaluation of femur sections
μCT analysis evaluating femur trabecular and cortical bone morphology
Competitive Advantage
TghRANKL osteoporosis model efficiently recapitulates human osteoporosis pathology and in combination to standardized evaluation procedures it offers the opportunity for reliable evaluation of the efficacy of anti-human RANKL biologics and denosumab biosimilars as well as novel osteoporosis treatments.
